Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1894562 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $3.03Day −1.94%Mkt cap $547M1Y −20.9%Off 52W high −56.3%Vol (1Y) 89.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,905 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest18.6% of sh out |
| Days to cover6.7d |
| 13F net flow (QoQ)−0.10% |
| Top-10 13F concentration61.9% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$4.6M |
| Earnings (TTM)-$198.4M |
| ROE−146.8% |
| Net margin−4342.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−12.7% |
| 1Y−20.9% |
| 3Y−79.9% |
| 5Y−80.3% |
| 10Y−86.0% |
| Since incept. (ann.)−16.2% |
Total return through 2026-07-29 · series begins 2015-11-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)89.7% |
| Ann. volatility (3Y)94.5% |
| Sharpe (1Y)0.10 |
| Sharpe (3Y)−0.10 |
| Max drawdown (1Y)−59.5% |
| Max drawdown (3Y)−92.4% |
| Beta (3Y vs SPY)3.16 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Alphabet Inc. | 16.6M | $58M | 9.17% | +0.0% |
| BlackRock, Inc. | 8.5M | $30M | 4.71% | +2.8% |
| STATE STREET CORP | 6.3M | $22M | 3.51% | +24.5% |
| ARK Investment Management LLC | 6.2M | $22M | 3.46% | +16.4% |
| T. Rowe Price Investment Management, Inc. | 5.5M | $19M | 3.04% | −22.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5M | $16M | 2.48% | new |
| Balyasny Asset Management L.P. | 4.1M | $14M | 2.28% | +32.0% |
| Casdin Capital, LLC | 3.2M | $11M | 1.75% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.28 | — | — | — |
| 2025-12-31 | 2026-03-03 | — | — | $838,000 | −61.6% |
| 2025-09-30 | 2025-11-07 | −$0.32 | — | $1.2M | +486.1% |
| 2025-06-30 | 2025-08-07 | −$0.41 | — | $1.1M | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
